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Abstract
OBJECTIVE—We previously reported that cardiac-restricted deletion of focal adhesion kinase 
(FAK) exacerbated myocyte death following ischemia/reperfusion (I/R). Here we interrogated 
whether targeted elevation of myocardial FAK activity could protect the heart from I/R injury.
METHODS AND RESULTS—Transgenic mice were generated with myocyte-specific 
expression of a FAK variant (termed SuperFAK) that conferred elevated allosteric activation. 
FAK activity in unstressed transgenic hearts was modestly elevated, but this had no discernable 
effect on anabolic heart growth or cardiac function. Importantly, SuperFAK hearts exhibited a 
dramatic increase in FAK activity and a reduction in myocyte apoptosis and infarct size 24–72 hrs 
following I/R. Moreover, serial echocardiography revealed that the transgenic mice were protected 
from cardiac de-compensation for up to 8 weeks following surgery. Mechanistic studies revealed 
that elevated FAK activity protected cardiomyocytes from I/R-induced apoptosis by enhancing 
NF-κB-dependent survival signaling during the early period of reperfusion (30 and 60 minutes). 
Moreover, adenoviral-mediated expression of SuperFAK in cultured cardiomyocytes attenuated 
H2O2 or hypoxia/re-oxygenation-induced apoptosis, whereas blockade of the NF-κB pathway 
using a pharmacological inhibitor or small interfering RNAs completely abolished the beneficial 
effect of SuperFAK.
CONCLUSIONS—Enhancing cardiac FAK activity attenuates I/R-induced myocyte apoptosis 
through activation of the pro-survival NF-κB pathway and may represent a novel therapeutic 
strategy for ischemic heart diseases.
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Cardiovascular diseases are the number one cause of death globally and current estimates 
indicate that as many as 1 out of 6 deaths/year in the United States can be attributed to 
coronary disease and associated myocardial ischemia1. While rapid reperfusion is necessary 
to reduce ischemia-dependent myocyte necrosis, it can also result in intracellular calcium 
overload and oxidative stress which can initiate apoptosis2. Importantly, while apoptosis can 
account for up to 60% of myocyte death within infarcted tissue3, this programmed cell death 
cascade (unlike necrosis) can be reversed by activation of pro-survival signals4, 5. Therefore 
defining the mechanisms that govern the transition between cardiomyocyte apoptosis and 
survival will undoubtedly have a significant impact on the generation of promising 
treatments to reduce ischemia-induced myocardial dysfunction.
Attachment of cells to the extracellular matrix results in the clustering of integrin receptors 
and initiates the recruitment of numerous structural and catalytically active signaling 
proteins to the adhesion complexes that are necessary for maintaining tissue integrity, 
conveying tensile strength, and for the transduction of growth and survival signals6. Several 
recent studies indicate that integrin signaling may play a pivotal role in preserving the 
myocardium from pathological stressors. For example, myocardial-restricted deletion of β1 
integrin in mice led to myocardial dysfunction in postpartum females and in male mice 
subjected to hemodynamic overload 7, 8. As well, mice with myocyte-restricted depletion of 
β3 integrin exhibited elevated cardiomyocyte apoptosis and concomitant heart failure 
following isoproterenol infusion 9. Moreover, the finding that human ischemic 
cardiomyopathy was associated with down-regulation of the muscle selective β1D-integrin 
and the integrin-activated kinase, focal adhesion kinase (FAK) supports the possibility that 
targeting this pathway may be beneficial in the prevention of ischemic human heart 
failure10.
Nearly two thirds of the known integrin heterodimers including all β1, β3 or β5 containing 
integrins couple to the non-receptor protein tyrosine kinase, FAK 11, 12 as do several growth 
factor receptors, including those activated by VEGFs and FGFs13, 14. FAK activation 
proceeds by a two-step process that involves dimerization and autophosphorylation of Y397 
which creates a high affinity SH2 binding site for the tyrosine kinase, Src. Once bound, Src 
phosphorylates FAK on two additional sites within the activation loop (Y576 and Y577) 
leading to further enhancement of FAK catalytic activity. FAK binding partners/substrates 
include the adapter proteins paxillin, CAS, and/or GRB 215–18 that can activate the ERK and 
JNK growth promoting Map Kinases. FAK also coordinates signaling to the pro-survival 
NF-κB19, 20 and Akt19 pathways through interactions with receptor-interacting protein and 
Pi3 kinase respectively. While FAK activity is necessary for myocyte proliferation and mid-
gestational heart growth, we recently showed that myocyte-specific deletion of FAK in the 
adult myocardium did not affect anabolic growth or basal contractility21. However, upon 
challenge, FAK-depleted hearts progressed to profound cardiac decompensation following 
pressure overload 21 and exhibited markedly increased myocyte apoptosis and infarct size 
relative to wt mice following ischemia/reperfusion (I/R) 22. Because our mechanistic studies 
supported a critical role for myocardial FAK in promoting NF-κB-induced survival 
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signaling following I/R, we predicted that enhanced myocardial FAK activity might provide 
cardioprotection from an ischemic insult.
To date, attempts to enhance pro-survival signaling in the myocardium by expression of up-
stream kinases have met with limited success, likely due to strategies that often lead to 
supra-physiological expression of constitutively active kinases. In these cases over-
expression alone can lead to striking changes in myocardial remodeling that culminate in 
phenotypes ranging from hypertrophy to heart failure and sudden death as has been observed 
in several transgenic mouse models with targeted expression of active Akt variants23–27. 
Since we hypothesized that transient elevation of FAK-dependent survival signals would be 
cardioprotective, while un-controlled activation could lead to detrimental remodeling, we 
sought to express a variant of FAK that requires signal-dependent activation but exhibits 
enhanced catalytic activity. Thus we took advantage of known mutations within the FAK 
activation loop (K578E/K581E) that mimic the charge transfer (and enhanced catalytic 
activity) induced by Src phosphorylation28. Herein, we found that transgenic mice with 
myocyte-restricted expression of this super-activatable FAK variant (termed SuperFAK) 
exhibited remarkable protection from I/R-dependent cell death. These studies provide the 
first evidence that FAK could be a tractable target for gene therapy and provide proof-of-
concept for a methodological approach to exploit post-translational modifications to enable 
spatial- and temporal control of kinase activation in vivo.
Methods
An expanded Methods section is available in the Online Data Supplement.
Generation of SuperFAK transgenic mice
The SuperFAK cDNA variant was kindly provided by Dr. Michael Schaller28. Cardiac-
specific transgenic mice with SuperFAK overexpression was achieved with a 3.4 kb piece of 
the cardiac βMHC promoter that was modified to prevent down-regulation at birth 29. All 
animals were housed in a University Animal Care Facility accredited by the American 
Association for Accreditation of Laboratory Animal Care and all procedures were approved 
by the University of North Carolina Institutional Animal Care and Use Committee.
Statistical analysis
All values are presented as means±SEM. Comparisons were performed by using unpaired 
Student t-test or one-way analysis of variance (ANOVA) with Tukey’s post-hoc test as 
appropriate. All tests were two-tailed and significance was accepted at p < 0.05.
Results
Generation of transgenic mice that confer enhanced allosteric FAK activity in the 
myocardium
We previously demonstrated that cardiac-restricted deletion of FAK exacerbates ischemia-
reperfusion (I/R) induced apoptosis and leads to enhanced cardiac decompensation 
following I/R or prolonged pressure overload21, 22. Since the toggling between pro-survival 
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and pro-apoptotic signals remains central to preventing irreversible damage to the heart30, 
we strove to determine whether enhanced FAK activity could salvage "at risk" myocytes in 
the ischemic heart. To address this critical issue, we generated transgenic mice that 
expressed a “Super-activatable” variant of FAK (SuperFAK) in cardiomyocytes. SuperFAK 
contains glutamic acid substitutions for two lysine residues in the activation loop of FAK 
(K578E, K581E) that renders the protein “primed” for allosteric activation (Supplemental 
Figure IA) 28, 31. SuperFAK has substantially increased catalytic activity in comparison to 
wild type FAK when expressed at comparable levels (Supplemental Figure IB). 
Nonetheless, SuperFAK is not constitutively active. Indeed, cells transfected with 
SuperFAK for 48 hr and maintained on tissue culture plastic exhibited comparable levels of 
FAK activity as non-transfected or LacZ-transfected cells (Figure 1A, left). However, when 
re-plated on a fibronectin-coated surface for 30 min, the SuperFAK transfected 
cardiomyocytes exhibited much more pronounced FAK activity (Figure 1A, right), 
indicating that SuperFAK confers enhanced allosteric activation.
Two novel mouse lines were generated in which a flag-epitope tagged SuperFAK (SF) 
transgene was expressed under the control of a truncated β-MHC promoter that was 
modified to drive cardiomyocyte-specific expression into adulthood 29. The so-named SF1 
and SF2 mice exhibited a persistent and myocardial-restricted increase (2- to 6-fold 
respectively) in basal cardiac FAK activity relative to age-matched non-transgenic (NTG) 
littermate control hearts (Figure 1B–D). Both SF1 and SF2 mice were born in the expected 
Mendelian frequency and no noticeable morbidity or mortality was observed for up to 18 
months of age.
Enhanced cardiomyocyte-specific FAK activity does not influence cardiac growth or basal 
cardiac function
We carefully assessed the consequence of elevated myocyte-restricted FAK activity on post-
natal myocardial growth in SF1 and SF2 mice. No significant differences were observed in 
myocardial shape or size (Supplemental Figure IIA), heart weight:body weight ratios 
(Supplemental Figure IIB) or cardiomyocyte cross-sectional area (Supplemental Figure 
IIC,D, III) when SF mice 8 weeks to 12 months of age were compared to age-matched 
littermate controls. To determine if elevated myocyte-specific FAK activity affected cardiac 
performance, we first measured left ventricular function by conscious echocardiography in 
young adult male SF2 and NTG control mice. No significant differences in either ejection 
fraction (EF) or fractional shortening (FS) were observed between these lines (Supplemental 
Figure IIE,F). As well, serial echocardiography in a second cohort of anesthetized mice 
revealed comparable LV wall thickness, chamber diameter, mass and function between NTG 
and SF2 mice from 1 to 12 months of age (Supplemental Figure IV). Hemodynamic 
measurements by cardiac catheterization also revealed no significant differences in intrinsic 
cardiac contractility or diastolic function between 12 month old NTG and SF2 mice 
(Supplemental Figure V). Taken together with our previous findings21, 32, these data 
indicate that FAK activity is neither necessary nor sufficient to promote anabolic cardiac 
growth. Moreover, while we and others previously found that FAK was necessary for the 
promotion of pathological cardiac remodeling following pressure overload21, 33, we found 
no signs of pathological hypertrophy in either SF line. qRT-PCR for the canonical 
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hypertrophy marker, ANF revealed no significant difference between SF2 and NTG 
(Supplemental Figure IIG). Levels of myocardial fibrosis as assessed by Masson’s 
Trichrome staining was also comparable between control and SF2 mice for up to 1 yr of age, 
consistent with our findings that systolic function was maintained in these mice 
(Supplemental Figure VI). In accordance with these findings, postnatal SF2 and NTG hearts 
exhibited comparable levels of cardiac Akt and ERK activity, signals that regulate anabolic 
and pathological hypertrophic growth of the post-natal heart (Supplemental Figure IIH).
Elevated FAK activity ameliorates adverse cardiac remodeling and dysfunction following 
I/R
Since we previously showed that cardiac-restricted deletion of FAK exacerbated I/R-
induced myocardial infarction22, we hypothesized that elevated FAK activity would confer 
cardioprotection in this setting. To this end, we subjected NTG and SF2 mice to 30 min of 
ischemia (induced by transient ligation of the LAD coronary artery) followed by reperfusion 
for 24 hr to 8 weeks and assessed infarct size and myocardial function. Evans blue/TTC 
staining showed that the relative area at risk (non-blue/total LV area) was comparable 
between the two groups, indicating a similar level of ischemia was induced following 
surgical ligation (data not shown). However, 24 hr following reperfusion, the SF2 mice 
exhibited a significantly decreased relative infarct size (white/non-blue area) when 
compared to control mice (control, 50.5±6.0% vs. SF2, 34.6±3.2%; p<0.05; n=6 for control 
and n=7 for SF2, Figure 2A top, B). A much greater difference was observed between the 2 
groups after 72 hr of reperfusion (control, 79.4±4.1% vs. SF2, 34.7±5.6%; p<0.001; n=5 for 
control and n=4 for SF2, Figure 2A bottom, B). Notably, in the NTG controls the relative 
infarct size increased dramatically from 24 to 72 hrs following I/R, while the SF2 mice 
exhibited no significant increase in infarct size during this critical time period. To determine 
whether SuperFAK expression promoted long term cardio-protection, cardiac function was 
monitored by conscious echocardiography at 2, 4 and 8 weeks post I/R in a third cohort of 
NTG and SF2 mice. Both interventricular septal and posterior wall thickness were much 
better preserved in the SF2 hearts (Supplemental Figure VII). Concomitantly, while both 
groups exhibited a decline in EF and FS following I/R, the SF2 hearts maintained 
significantly greater function than the NTG controls (Figure 2C,D). Ultimately, I/R-induced 
chamber dilatation was observed in the NTG but not SF2 hearts at the 4 and 8 week time 
points (Supplemental Figure VII). Collectively, these data indicate that enhanced myocardial 
FAK activity protects the myocardium from I/R-dependent cell death and promotes 
functional recovery following an ischemic insult.
Elevated FAK activation attenuates cardiomyocyte apoptosis following ischemia/
reperfusion
Ischemia/reperfusion induced myocyte death results from irreversible (necrotic) and 
reversible (apoptotic) signals. Since our previous studies indicated that FAK depletion 
renders cardiomyocytes more susceptible to ischemia-induced apoptosis, we reasoned that 
enhanced FAK activity might limit cardiomyocyte apoptosis following I/R. We first sought 
to determine the extent to which SuperFAK is activated in ischemic myocytes. To aid in the 
demarcation of the ischemic zone, I/R-treated mice were injected with hypoxyprobe-1 
(pimonidazole hydrochloride) which forms protein adducts in cells with a pO2 of 10 mm Hg 
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or less that can be detected by immunostaining34. As shown in figure 3A, sham SF2 hearts 
contained little immunoreactivity for hypoxyprobe-1, while those subjected to I/R for 24 hr 
revealed intense focal reactivity, typical of hypoxia. Consistent with previous studies from 
us and others indicating that wt FAK was activated following I/R 22 or ischemic pre-
conditioning 35, co-staining with the pFAK(Y397) antibody revealed that FAK activity was 
relatively low in sham SF2 hearts, but was markedly induced within the hypoxic myocytes 
in I/R treated SF2 hearts (Figure 3A). As expected, the magnitude of ischemia-induced FAK 
activation was much higher in SF2 hearts than control hearts subjected to I/R despite a 
similar extent of hypoxyprobe staining (Figure 3B and data not shown), indicating that 
SuperFAK is primed for robust activation in response to myocyte hypoxia. We next asked 
whether ischemic myocytes with elevated FAK activity were more resistant to I/R-induced 
apoptosis. As shown in figure 3B–C, the number of TUNEL-positive myocytes 24 hr 
following I/R was significantly lower in the SF2 hearts than in NTG controls in both the 
ischemic border zone and in remote regions. Moreover, SF2 hearts exhibited a stark 
reduction in I/R induced cleaved caspase 3 levels as assessed by immunohistochemistry 
(Supplemental Figure VIII). Taken together with our results that infarcts in SF2 hearts did 
not increase between 24 and 72 hrs following I/R (time points in which apoptosis 
contributes significantly to myocyte death) these studies provide strong evidence that 
enhanced FAK activity can protect myocytes from ischemia-induced apoptosis. Importantly, 
capillary and coronary vascular density was comparable between control and SF2 hearts 
(Supplemental Figure IX), indicating that the beneficial effect of elevated FAK activity was 
likely myocyte autonomous and was not due to enhanced collateral blood flow.
Elevated FAK activity protects cultured cardiomyocytes from oxidative stress-induced 
apoptosis
We developed an in vitro assay to further test whether elevated FAK activity confers 
protection from ischemia-induced programmed cell death in a cell autonomous fashion. To 
this end, we infected primary neonatal rat cardiomyocytes (NRCM) with adenoviruses 
expressing GFP or SuperFAK and subjected these cells to oxidative stress by treatment with 
10µM H2O2 or by incubation in low O2 as previously described22. Oxidative stress is known 
to play a critical role in I/R-induced cardiomyocyte apoptosis2, and we found that treatment 
of cultured cardiomyocytes with 10µM H2O2 for 5 hr induced marked apoptosis in non-
infected or GFP-infected cardiomyocytes (as assessed by TUNEL labeling) while 
significantly fewer TUNEL-positive cells were found in SuperFAK-infected cultures (Figure 
4A, Supplemental Figure X). SuperFAK also decreased TUNEL labeling in NRCM 
subjected to hypoxia (1% O2) for 2 hr followed by re-oxygenation for 1 hr, which closely 
mimics the hypoxia observed following I/R in vivo (Figure 4B) 22. As a secondary measure 
of apoptosis, we evaluated cleavage of caspase 3 in cell lysates by Western analysis. As 
shown in supplemental figure X, H2O2 treatment led to cleavage of caspase 3 in GFP- 
infected but not SuperFAK-infected NRCM. Taken together, these data indicate that FAK 
acts in a cell autonomous fashion to protect myocytes from oxidative stress-induced 
apoptosis.
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SuperFAK enhanced nuclear translocation and transcriptional activity of NF-κB in cardiac 
myocytes
Since we recently showed that FAK was required for I/R–mediated activation of NF-κB, 
and some studies indicate that NF-κB protects cardiomyocytes from I/R-induced 
apoptosis 22, 36–38, we interrogated the activity of this pathway in NTG and SF2 hearts. As 
shown in figure 5, SF2 hearts subjected to 30 min of ischemia followed by 30 or 60 min of 
reperfusion exhibited increased levels of phosphorylated Ser32/36 IκBα relative to control 
hearts with a concomitant decrease in IκBα levels, and enhanced phosphorylation of p65 
(Ser536) that returned to baseline by 24 hr of reperfusion (Figure 5A,B, Supplemental 
Figure XI). As well, SF2 hearts exhibited enhanced p65 NF-κB nuclear localization, 
enhanced DNA binding activity at 60 min post I/R and higher levels of the NF-κB-
transcriptional targets XIAP, Bcl-2 and Bcl-xl 39 at 24 hr post I/R (Figure 5C–E, 
Supplemental Figure XII). Collectively, these data indicate that elevated FAK activity 
transiently augmented NF-κB-dependent survival signaling. Of note, while I/R also induced 
transient activation AKT and ERK (as assessed by Western blotting with activation-specific 
antibodies), the levels of activation did not differ between NTG and SF2 hearts 
(Supplemental Figure XI).
FAK-dependent resistance to oxidative stress requires NF-κB signaling
To confirm that regulation of NF-κB was attributable to a primary change in myocyte FAK 
activity, we next examined activation of this survival pathway in cultured cardiomyocytes. 
As expected, SuperFAK expressing cardiomyocytes that were plated on FN to induce FAK 
activity exhibited a decrease in IκBα and a concomitant increase in NF-κB activity 
(Supplemental Figure XIII) and expression of XIAP, Bcl-2 and Bcl-xl (Figure 6A) when 
compared to non-infected or GFP-infected cells. To determine the functional importance of 
this survival pathway with respect to SuperFAK-dependent protection from oxidative stress, 
we next explored whether inhibition of NF-κB signaling would restore myocyte apoptosis in 
SuperFAK-expressing cardiomyocytes. As shown in figure 6A, treatment with JSH-23, a 
cell-permeable inhibitor of NF-κB p65 nuclear translocation, suppressed the capacity of 
SuperFAK to induce XIAP, Bcl-2 and Bcl-xl expression. Moreover, while treatment of 
JSH-23 had little effect on H2O2- or hypoxia/re-oxygenation-induced apoptosis in GFP 
expressing cells, it completely abolished the protection conferred by SuperFAK 
overexpression (Figure 6B, C). Indeed, in the vehicle control group, the number of TUNEL 
positive SuperFAK expressing cardiomyocytes was significantly lower than GFP-expressing 
cardiomyocytes exposed to oxidative stress, while the numbers of TUNEL positive 
SuperFAK- and GFP-expressing cardiomyocytes were comparable in cultures pre-treated 
with JSH-23. We next utilized siRNAs targeted towards the p65 NF-κB transcript to 
confirm a role for this pathway in SuperFAK-mediated myocyte survival. As shown in 
figure 6D–F, treatment of cultured cardiomyocytes with NF-κB siRNAs led to an 
approximate 90% reduction of p65 levels as assessed by Western blotting, and nearly 
completely reversed the beneficial effect of SuperFAK expression when cells were exposed 
to H2O2 or hypoxia/re-oxygenation. In combination, these results indicate that induction of 
the NF-κB pathway is a major mechanism by which elevated FAK activity confers 
cardioprotection.
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Ischemic heart disease is a significant cause of morbidity and mortality worldwide, thus an 
enormous interest exists for the development of cardioprotective gene therapies. One 
potentially promising avenue involves attempts to enhance the activity of intrinsic pro-
survival signals that are hard-wired in post-mitotic cardiomyocytes to impart relatively high 
levels of resistance to oxidative stress. Under physiological conditions, most signaling 
molecules exhibit transient waves of activation to achieve the appropriate biological 
response and one of the current challenges of this therapeutic approach is how to achieve 
such spatial and temporal control of pro-survival signals, since prolonged activation can lead 
to maladaptive cardiac remodeling 25–27. We previously reported that FAK plays an 
important role in the induction of intrinsic survival pathways in cardiomyocytes following 
ischemia/reperfusion and sought to explore whether targeted FAK activation might 
ameliorate ischemia-induced apoptosis. To this end, we utilized the knowledge that 
mutations in the activation loop of FAK enhanced catalytic activity but also required signal-
dependent activation for maximal induction. We found that transgenic mice that expressed 
this “super-activatable” variant of FAK (SuperFAK) in the myocardium exhibited elevated 
FAK activity in un-stressed hearts without consequence on cardiac growth or function. 
Importantly, FAK activity was profoundly increased in SuperFAK expressing hearts 
following I/R and these hearts displayed remarkable cardioprotection. Indeed, hearts with 
transiently elevated FAK activity exhibited a dramatic reduction in myocyte apoptosis and 
infarct size and were protected from myocardial infarction-induced cardiac de-
compensation. We reason that the attenuation of myocyte apoptosis and initial infarct size 
by FAK activation leads to a long-standing benefit in contractile performance.
It is important to note that our studies reflect a beneficial effect of FAK when activated 
solely in cardiomyocytes. Interestingly, a recent study revealed that germline deletion of the 
ECM component fibronectin-EDA, a major fibronectin splice variant, did not affect infarct 
size, but prevented adverse ventricular remodeling following myocardial infarction; an 
effect attributed to reduced activation of leukocytes and cardiac fibroblasts that resulted in 
lower levels of inflammation and metalloproteinase 2 and 9 activities 40. While FAK activity 
was not directly evaluated in these hearts, a separate study revealed that treatment of 
fibroblasts with fibronectin-EDA induced myofibroblast differentiation by a mechanism that 
involved binding to the α4β7 integrin and inducing integrin-dependent activation of FAK41. 
These studies corroborated earlier findings that FAK can induce inflammatory cytokine 
production in fibroblasts42. While myofibroblasts (i.e. activated cardiac fibroblasts) are 
important for the initial healing responses following myocardial infarction, these cells also 
contribute to pathologic fibrosis and detrimental cardiac remodeling. Thus, one might expect 
that wide-spread activation of FAK throughout the myocardium would not likely provide as 
beneficial an effect as was observed herein following specific cardiomyocyte activation and 
caution should be taken when devising therapeutic strategies to activate this molecule for 
cardioprotective purposes.
Our mechanistic studies revealed that elevated FAK activity protected cardiomyocytes from 
oxidative-stress induced apoptosis, at least in part, through enhanced intrinsic NF-κB-
dependent survival signaling. These findings confirm and extend our previous loss-of-
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function studies indicating that FAK was necessary for NF-κB activation in cardiomyocytes 
exposed to oxidative stress and studies from others indicating that FAK was required for 
NF-κB activation and survival of fibroblasts exposed to cytokines20 and endothelial cells 
exposed to shear stress43. FAK has been shown to induce NF-κB activation by forming a 
complex with the TNF receptor-associated factor 2 (TRAF2) and RIP and facilitating the 
phosphorylation/activation of the upstream kinase IKK44. Since, we observed increased 
phosphorylation of the IKK substrate, IκBα in the SF2 hearts relative to controls, it is likely 
that a similar mechanism resulted in FAK-dependent activation of NF-κB signaling in these 
hearts. However, recent findings by Petzold et al. indicate that FAK may facilitate NF-κB 
activation by different mechanisms in cytokine vs. shear stress-induced stress signaling43. 
These authors found that following mechanical signals, FAK acts in a direct fashion to 
promote NF-κB phosphorylation and activation43. Although we did find elevated activity of 
the IKK kinase and decreased levels of IκB in the SF2 hearts, our data do not rule out the 
possibility that I/R-dependent activation of FAK also directly augments NF-κB activity.
Cardiomyocytes are known to be particularly sensitive to the levels of NF-κB-dependent 
survival genes. Indeed studies in cultured myocytes indicated that NF-κB suppressed 
mitochondrial defects and apoptosis through transcriptional up-regulation of survival genes 
(including Bcl-2, Bcl-xl and XIAP) or by silencing pro-apoptotic genes such as 
BNIP3 36, 45, 46. However, the function of NF-κB in the intact heart is controversial as it has 
been reported to induce both pro-survival and pro-apoptotic signals37, 38, 47, 48. More recent 
studies indicate that timing of activation may be causal for this disparity 36, 47, 48. Thus, 
while acute myocyte NF-κB activation promoted cardioprotection, chronic myocyte NF-κB 
activation led to an exacerbated inflammatory response and resulted in maladaptive 
remodeling 36. Our studies are consistent with a FAK-dependent cardioprotective effect of 
transient NF-κB activation as we found elevated NF-κB activity in the SF2 hearts 30 to 60 
minutes following I/R and a return to baseline by the 24 hr time point. To determine which 
cell type was responsible for elevated NF-κB activity in SF2 hearts, immunohistochemistry 
was performed with an NF-κB p65-specific antibody. Our results showed that enhanced 
nuclear translocation of NF-κB p65 was present in cardiac myocytes of SF2 hearts when 
compared with NTG hearts (Figure 5D), though we cannot exclude the possibility that NF-
κB is activated in additional resident heart cells, like the endothelium, in which I/R has been 
reported to lead to activation of NF-κB49. Moreover, although we did not observe enhanced 
activation of other major survival signals such as ERK1/2 or AKT in the SF2 hearts, it is 
formally possible that other FAK-dependent survival pathways contribute to the 
cardioprotective effects of FAK. Nonetheless, our finding that blockade of NF-κB-
dependent signals reverses the protection induced by SuperFAK expression in 
cardiomyocytes exposed to oxidative stress indicates that intrinsic NF-κB activation does 
play a causative role in FAK-mediated myocyte survival.
We and others have previously identified a significant role for FAK in mediating the robust 
growth responses necessary for both mid-gestational cardiac development and for the 
promotion of pressure-overload induced myocyte hypertrophy 21, 33, 50 but not for anabolic 
cardiac growth. Subsequent mechanistic studies indicated that basal FAK activity in 
embryonic hearts was necessary to repress p38 kinase activity and to promote 
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cardiomyocyte cell cycle progression through G2/M 32. However, in terminally 
differentiated cardiomyocytes, we found that FAK activity was necessary for ERK-
dependent promotion of pathological hypertrophic growth32. While postnatal SF2 hearts 
exhibited elevated levels of FAK activity, no change in cardiac ERK activity was observed, 
consistent with previous findings that SuperFAK did not enhance adhesion- or serum-
stimulated ERK activation in cultured cells 28. Concomitantly, adult SF2 hearts exhibited no 
signs of pathological hypertrophic remodeling. Indeed, SF2 and littermate control NTG mice 
had comparable heart weight/body weight ratios, cardiomyocyte cross-sectional area, ANF 
expression, and cardiac function. These results confirm and extend previous studies 
indicating that overexpression of wt FAK in NRCM did not increase stretch-induced ANF 
expression 51. Taken together, these data indicate that FAK is necessary but not sufficient to 
promote ERK activation and pathological hypertrophic growth.
In sum, there are two major findings from the studies presented herein 1) they support the 
feasibility of exploiting mutations in the activation domain of kinases to augment the 
successes of gene therapy approaches and 2) they indicate that methodologies to enhance 
FAK activity (including administration of upstream agonists52, 53, or possibly via ischemic 
pre- and post-conditioning35, 53 or heat shock35) may represent a novel therapeutic strategy 
for ischemic heart diseases. Since several recently developed chemotherapeutic agents that 
target receptor tyrosine kinases upstream of FAK, including sunitinib and imatinib, induce 
myocyte apoptosis and cardiomyopathy 54, 55, it will be of future importance to evaluate 
whether enhancing FAK activation might also be an effective strategy to preserve 
myocardial function in this setting.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Generation of cardiomyocyte-specific SuperFAK transgenic mice
(A) COS7 cells were non-transfected (NT), transfected with LacZ control or SuperFAK (SF) 
and grown to confluence (adherent) or re-plated on fibronectin (FN)-coated dishes for 30 
min. Western blotting was performed with indicated antibodies. (B) Levels of basal 
myocardial FAK activity in 1-month-old SuperFAK transgenic (SF1 and SF2) and non-
transgenic (NTG) mice. (C) Detection of flag-tagged SuperFAK in various tissues revealed 
myocardial-restricted expression in SF2 mice. (D) SF2 mice exhibit elevated levels of FAK 
activity during development.
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Figure 2. Targeted FAK activation provided protection from I/R injury
Non-transgenic (NTG) littermate control and SF2 mice at 8–12 weeks of age were subjected 
to 30min of ischemia followed by reperfusion. (A) Representative heart slices at 24h or 72h 
post I/R stained with Evans blue/TTC showing infarct area (Evans blue and TTC unstained, 
white) and area at risk (Evans blue unstained, shown as red and white). (B) Infarct size (ratio 
of infarct area to area at risk) was significantly decreased in the SF2 mice compared with 
NTG mice 24h (NTG, n=6; SF2, n=7) or 72h (NTG, n=5; SF2, n=4) post I/R. * p < 0.05; 
*** p < 0.001. (C,D) LV ejection fraction (EF) and fractional shortening (FS) were 
evaluated by conscious echocardiography before, 2, 4, and 8 weeks post I/R. NTG, n=6; 
SF2, n=5. * p < 0.05 vs. NTG; ** p < 0.01 vs. NTG; *** p < 0.001 vs. NTG. Data are 
expressed as mean ± SEM.
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Figure 3. FAK was activated in hypoxic cardiomyocytes and myocyte FAK activation conferred 
protection from I/R induced apoptosis
(A) SF2 mice were injected with 60 mg/kg (i.p.) hypoxyprobe-1 and sacrificed at 24h post 
I/R or sham operation. Heart sections were stained with mouse anti-hypoxyprobe-1 antibody 
to label hypoxic cells (red), and rabbit anti-pFAK (Y397) to show FAK activation (green). 
Signals for hypoxyprobe-1 and pFAK (Y397) were dramatically increased and co-localized 
(yellow-orange) following I/R compared with sham-operated SF2 hearts, indicative of FAK 
activation in hypoxic myocardial cells. Nuclei were labeled with DAPI (blue). Scale bar = 
20µm. (B) At 24h post I/R, the ischemic border zone of SF2 hearts displayed elevated FAK 
activity (green) and decreased TUNEL staining (red) when compared with non-transgenic 
(NTG) littermate control hearts. Nuclei were labeled with DAPI (blue) and cardiomyocytes 
labeled with cardiac troponin T (cTnT, white). Scale bar = 20µm. (C) Quantification of 
TUNEL-positive myocytes in the infarct border (left) and remote (right) region showed 
significantly less apoptotic cardiomyocytes in the SF2 hearts than in the control hearts. 
NTG, n=3; SF2, n=4 (100–200 cells/heart). * p < 0.05 vs. NTG; ** p < 0.01 vs. NTG. Data 
are expressed as mean ± SEM.
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Figure 4. Overexpression of SuperFAK protected cultured cardiomyocytes from oxidative stress-
induced apoptosis
(A) Quantification of TUNEL-positive myocyte nuclei showing a significant decrease of 
apoptosis following H2O2 treatment in SuperFAK-infected neonatal rat cardiomyocytes 
(NRCM) when compared with non-infected or GFP-infected NRCM. Results are mean ± 
SEM of 4 independent experiments. * p < 0.05. (B) Non-infected, GFP- or SuperFAK-
infected NRCM were subjected to hypoxia for 2h followed by re-oxygenation for 1h. 
Cellular apoptosis assessed by TUNEL staining was significantly decreased by 
overexpression of SuperFAK compared with intact or GFP-infected cells. Data represent 
mean ± SEM of 3 independent experiments. * p < 0.05.
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Figure 5. FAK enhanced nuclear translocation and transcriptional activation of NF-κB in 
cardiac myocytes
(A–D) Non-transgenic (NTG) littermate control mice and SF2 mice were subjected to 30min 
of ischemia followed by 30min or 60min of reperfusion. Border zone of the infarcted 
myocardium was collected for subcellular fractionation or immunohistochemistry. (A) 
Representative immunoblots of whole cell lysates 30min and 60min post I/R with GAPDH 
as a loading control. (B) Quantification of protein expression in whole cell lysate at 60min 
post I/R showed a significant increase of phospho-NF-κB p65 (S536), phospho-IκBα 
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(S32/36) and a decrease of total IκBα in the SF2 group when compared with control hearts. 
NTG, n=3; SF2, n=4. * p < 0.05 vs. NTG. (C) Representative immunoblots of nuclear and 
cytosolic fractions 30min and 60min post I/R. Histone H3 served as a nuclear loading 
control and GAPDH as a cytosolic loading control. See supplemental figure XII for 
quantification. (D) Confocal images of NTG and SF2 hearts 60min post I/R immunolabeled 
for NF-κB p65 (green), cardiac troponin T (cTnT, red) and DAPI (blue). SF2 hearts 
exhibited increased NF-κB p65 signal in the nuclei of cardiac myocytes (arrows). Scale bar 
= 20µm. (E) Protein levels of XIAP, Bcl-2 and Bcl-xl were significantly higher in the SF2 
heart than in controls at 24h post I/R. See supplemental figure XII for Western images. 
NTG, n=3; SF2, n=4. * p < 0.05 vs. NTG. ** p < 0.01 vs. NTG. Data are mean ± SEM.
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Figure 6. Blockade of NF-κB pathway abrogated the anti-apoptotic effect of FAK activation
(A) Neonatal rat cardiomyocytes (NRCM) overexpressing GFP or SuperFAK were treated 
with DMSO or the NF-κB inhibitor JSH-23 (25µM) for 12h. Cell lysates were probed with 
indicated antibodies by Western blotting, with GAPDH as a loading control. SF, SuperFAK. 
(B,C) NRCM were infected with adenoviruses overexpressing GFP or SuperFAK for 48h. 
Cells were then incubated with DMSO or the NF-κB inhibitor JSH-23 (25µM) for 2h before 
stimulation with H2O2 (B) or hypoxia/re-oxygenation (C) as described in Methods. TUNEL 
staining revealed that overexpression of SuperFAK significantly decreased myocyte 
apoptosis in response to oxidative stress. However, inhibition of NF-κB completely 
abolished the protective effect of SuperFAK. Data represent mean ± SEM of 4 independent 
experiments (200–400 cells/experiment). * p < 0.05. (D) NRCM were transfected with 
control siRNA (si-Control) or NF-κB p65 siRNA (si-p65) for 24h followed by infection 
with GFP or SuperFAK adenoviruses for 48h. Western blotting showed >90% knockdown 
of NF-κB p65. Images are representatives of 3 independent experiments. (E,F) NRCM in 
(D) were treated with H2O2 (E) or hypoxia/re-oxygenation (F). TUNEL staining revealed 
that knockdown of NF-κB completely abolished the protective effect of SuperFAK. Data 
represent 4 independent experiments. * p < 0.05.
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